The UK has reached a critical inflection point in its digital journey. Over $40 billion in fresh commitments from global ...

Yarrow's Graves' disease pick Finally, this week – so far at least – Yarrow Bioscience has paid $70 million upfront for ex-China rights to an antibody targeting the thyroid-stimulating hormone ...

The Women in AI Healthcare event series - hosted by Real Chemistry in collaboration with Pharma Brands – brings together ...

Regulators in the UK and US are the first to approve GSK's Exdensur, a long-acting, twice-yearly IL-5 inhibitor for severe ...

Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as a perioperative therapy for ...

Shares in the company rose more than 35% on the strength of the data, which could put DBV on track to bring the immunotherapy ...

Patients are often stabilised for years on somatostatin analogues; however, progression eventually necessitates ...

Here’s what most pharma professionals don’t want to hear: if you're a scientist or physician who spent your career in pharma, ...

Privately-held drug developer LIB Therapeutics has claimed FDA approval for a new once-monthly PCSK9 inhibitor – Lerochol – ...

The ACIP has been accused of cherry-picking data on side effects – attempting to perpetuate a debunked link between the shots ...

GLP-1 receptor agonists have captured global attention for their ability to drive weight loss and improve metabolic health.

The clinical trial industry is at a critical juncture where traditional methods are proving insufficient for managing today’s ...